While TNBC and HER2+ BC are two distinct molecular subtypes of BC, they share certain similarities in clinicopathological characteristics and treatment challenges, such as high histologic grade, more aggressive biology, early metastatic potential, and higher rates of pCR with neoadjuvant treatment, compared to hormone receptor-positive BCs [30,31,32]. The gene discussed is ERBB2; the disease is breast cancer.